All News

RA Hands Difficult deformity

BMI Most Impairs Treatment Response in Rheumatoid Arthritis

d Jack Cush, MD

Using a large cohort of rheumatoid arthritis (RA) patients, Tumor-Necrosis Factor inhibitors (TNFi) were compared to non-TNFi biologic therapies and showed that poorer responses were seen in obese and underweight patients, with no clear superiority of non-TNFi therapy over TNFi therapy in an

Read Article
PsA, PSO, nail

Two Year Guselkumab Benefits in Psoriatic Arthritis

d MedPage Today

Patients enrolled in one of the pivotal trials of guselkumab (Tremfya) as therapy for psoriatic arthritis (PsA) and followed for 100 weeks continued to show significantly reduced symptoms relative to pretreatment baseline, researchers said.

Read Article
CV,risk,MI,heart,cardiac

CV Risk Management in Rheumatic Disease Patients

d Jack Cush, MD

The European League against Rheumatism (EULAR) has developed recommendations for cardiovascular risk (CVR) management in rheumatic disease patients based on literature review and expert consensus.

Read Article
Pills.men_.jpg

Rheumatoid Arthritis Nonadherence is Multifactorial

d Jack Cush, MD

The consequences of medication non-adherence (NA) in rheumatoid arthritis (RA) care are numerous and damaging.  A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clini

Read Article
New 2021 JIA guidelines w 55 recommendations, 36 conditional and 19 strong. #RWCS2022 @RWCSmtg Dr Susan Shenoi https://t.co/CMETQeOdch
Dr. John Cush RheumNow ( View Tweet)
ACR RISE registry study looked at Rx of 3276 Sarcoidosis pts from 184 rheum practices finds 59.3% rx w/ steroids (24% prolonged steroids). and 12.1 Rx w/ biologics or tsDMARDs, mostly TNFi (inflx). But wide practice-level variations in Rx https://t.co/95CEDai2uN

Links:

Dr. John Cush RheumNow ( View Tweet)

MMWR study of shows 2 dose mRNA COVID vax during pregnancy was 61% effective preventing infant COVID. Among 176 infants hosp w/ COVID-19, 84% were born to mothers who were not vaccinated during pregnancy.https://t.co/mWgHHcL05u

Links:

Dr. John Cush RheumNow ( View Tweet)

Saphnelo (anifrolumab) has been approved in the European Union as an add-on therapy for the treatment of adult with moderate to severe, active, autoantibody-positive systemic lupus erythematosus (SLE), despite receiving standard therapy.https://t.co/fdZAFFDrYW

Links:

Dr. John Cush RheumNow ( View Tweet)

Study of 25/306 SLE patients (8.2%) who developed 29 episodes of Pulmonary Hemorrhage (PH). 1st manifestation . PH assoc w/ Renal dz, high SLE activity during PH; PH mortality w/ Renal failure & mech ventilation. https://t.co/ydJkgf5BFB

Links:

Dr. John Cush RheumNow ( View Tweet)

We have an exciting agenda for #RNL2022, with topics ranging from Psoriatic Disease for Rheumatologists to Advances in Psoriasis Management and speakers from around the world, including Dr. Bruce Strober. Register Today! https://t.co/VZ2hmxAmDw https://t.co/AJbSLNXDql

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Virginia Steen at #RWCS2022. On scleroderma lung Dz that worsens outcomes https://t.co/n7IV8UVI2N https://t.co/kLmiKiseur
Dr. John Cush RheumNow ( View Tweet)
Rheumatoid Arthritis Nonadherence is Multifactorial A 6-month prospective cohort study of RA patients shows NA to vary according to drug type and be related to psychological, communicational, logistic, sociodemographic or clinical factors. https://t.co/FWamPS2fTQ https://t.co/EtoStfdTsI

Links:

Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents on paraneoplastic syndromes. Many autoantibodies have been possibly implicated. #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xx54hAKY3C
Dr. John Cush RheumNow ( View Tweet)
1st approved Rx for neuromyelitis optical (Device syndr). Eculizumab, C5a inhibitor, weird effective at preventing relapses of NMO #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/a6LyTi3LXL
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents treatment of Stiff Man syndrome why muscle relaxants, benzos, IVIG?? Poor outcomes nevertheless #RWCS2022 https://t.co/n7IV8UVI2N https://t.co/xDXJCM34aO
Dr. John Cush RheumNow ( View Tweet)
Dr Eric Ruderman presents on rare Stiff Man syndrome at #RWCS2022 https://t.co/n7IV8UVI2N
Dr. John Cush RheumNow ( View Tweet)
EMA has posted its intent to review the safety of JAK inhibitors used to treat several chronic inflammatory disorders (RA, PsA, JIA, AS, UC, atopic dermatitis) based on the release of the Pfizer tofacitinib A3921133 study https://t.co/loG7zWBWHs

Links:

Dr. John Cush RheumNow ( View Tweet)

Mortality of Cryoglogulinemia has declined between 1999 and 2018 freom 0.4 deaths per million to 0.19. Cryo found in 39% of HCV(2009–2013) down to 26% (2014–2018). Prevalence and deaths dropped witn introduction of HCV antiviral Rx https://t.co/h9rL1ftI0n

Links:

Dr. John Cush RheumNow ( View Tweet)

Challenges in Lupus: -Mortality greatest in 1st yr -Dx Delays 6.4 yrs -Long-term complications increased 50 fold -Steroids worsen long-term outcomes -Health care costs increased 3 to 5 years prior to Dx -Mean delay in drug starts after Dx =177 days https://t.co/QUbsIQtcRa https://t.co/zAMUp99ecg

Links:

Dr. John Cush RheumNow ( View Tweet)
Olumiant (baricitinib) studies in Lupus halted by Lilly due to mixed results in phase 3 trials. While the BRAVE-1 study showed 4-mg BARI meeting primary endpoint at 52 weeks; the Brave-II failed to do same & failed key secondary endpoints https://t.co/XBmo15UCYl

Links:

Dr. John Cush RheumNow ( View Tweet)

×